MustGrow reports growth in global patent portfolio


  • The intellectual property portfolio derived from Mustard has evolved significantly in quantity and scope.

  • Patents have been filed on six continents.

  • The patent portfolio has grown from 23 to 84 within three years.

Saskatoon, Saskatchewan–(Newsfile Corp. – March 8, 2023)- MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (The “Pursue” or “Must grow“), is pleased to report the growth of its intellectual property portfolio (the “IP portfolio’) in quantity and scope, particularly in relation to the company’s patents.

“The growth of our IP portfolio increases the potential commercial value of MustGrow’s organic mustard-derived crop protection and food preservation technologies through potential product sales, royalties and royalties and/or other commercial transactions – all of which would help increase shareholder value,” noted Corey Giasson, President and CEO of MustGrow.

MustGrow’s global IP portfolio has grown from a total of 23 to 84 issued and pending patents over the past three years. Out of a total of 84 patents, 62 were granted, an increase from the 18 patents granted three years ago. The IP portfolio also includes trade secrets and protects MustGrow’s mustard-derived technology across six continents, including different compositions, production processes and end-uses. The IP portfolio covers MustGrow’s three main focus areas: pre-sowing soil fumigation, post-harvest food preservation and bioherbicide.

As of 2021, MustGrow has been developing its biological technologies with four global partners – Janssen PMP, Bayer, Sumitomo Corporation and NexusBioAg – and retains the ability to commercialize all of its partner-generated data and discoveries. These agreements have allowed MustGrow to significantly accelerate technology development and potential future commercialization. MustGrow continues to innovate in biological crop protection and food preservation with the breadth and depth of its IP portfolio driven by laboratory, greenhouse and field trials.


About MustGrow

MustGrow is an agricultural biotech company developing organic biopesticides and bioherbicides by harnessing the mustard plant’s natural defense mechanism to protect the global food supply from diseases, insect pests and weeds. MustGrow and its leading global partners – Janssen PMP (pharmaceutical division of Johnson & Johnson), Bayer, Sumitomo Corporation and NexusBioAg of Univar Solutions – are developing mustard-based organic solutions to replace potentially harmful synthetic chemicals. Over 150 independent tests have been conducted confirming MustGrow’s safe and effective approach to plant and food protection. Subject to regulatory approval, MustGrow’s patented technology could be applied through injection, standard drip or spray devices, enhancing functionality and performance characteristics. Now a platform technology, MustGrow and its global partners are pursuing applications in diverse industries, from pre-sowing soil treatment and weed control to post-harvest disease control and food preservation. MustGrow has approximately 49.7 million ordinary shares issued and outstanding and 55.6 million fully diluted shares. Visit www.mustgrow.ca for more details.


“Corey Giasson”

Director & CEO
Telephone: +1-306-668-2652

MustGrow Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” that involve known and unknown risks, uncertainties and other factors that may affect MustGrow’s results, performance or achievements.

Generally, forward-looking information is identified by the use of forward-looking terms such as “plans,” “expects,” “is expected,” “budget,” “estimates,” “intends,” “anticipates,” or “has not predicted” or ” believe” or variations of such words and expressions or statements that certain actions, events or results “may”, “could”, “would”, “occur” or “be achieved”. Examples of forward-looking statements in this press release include, but are not limited to, statements MustGrow to: (i) increase the potential commercial value of its organic mustard-derived crop protection and food preservation technologies through potential product sales, royalties and royalties, and/or other commercial transactions; and (ii) the potential results to be derived from the efforts of the company in relation to its IP portfolio in order to further increase shareholder value.

Forward-looking statements are subject to a number of risks and uncertainties that could cause MustGrow’s actual results to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, they may not be Representation that they will have the anticipated consequences or impact on MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include the following: (i) the preferences and decisions of the agricultural authorities with respect to the deadlines for the product approval; (ii) the ability of MustGrow’s partners to perform obligations under their respective agreements; and (iii) other risks more fully described in MustGrow’s annual information form for the year ended December 31, 2021 and other ongoing disclosure documents filed by MustGrow with the relevant securities regulatory authorities, which are available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, subject to the limitations, assumptions and notes contained therein.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States.

Neither the TSXV, its Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets have approved the contents of this press release or accept responsibility for the adequacy or accuracy of this press release.

© 2023 MustGrow Biologics Corp. All rights reserved.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/157599

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *